Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Global publication plans

- PMLiVE

Collaborating for change in rheumatology

Elevating the standard of care through multistakeholder consensus

- PMLiVE

An Invisible Pandemic

Join Inizio Evoke Europe and University College London’s (UCL) Faculty of Brain Sciences for an unmissable discussion on our revolutionary new white paper, Transforming Bias in Healthcare. This webinar will...

- PMLiVE

Eli Lilly partners with OpenAI to discover antimicrobials for drug-resistant pathogens

Antimicrobial resistance has been declared by WHO as one of the top ten global public health threats

- PMLiVE

AstraZeneca’s Imfinzi combination shows promise in phase 3 bladder cancer study

More than 614,000 new cases of the disease are diagnosed globally every year

- PMLiVE

Novo Nordisk shares positive results for Mim8 in late-stage haemophilia A trial

The inherited bleeding disorder accounts for up to 85% of the 1,125,000 global haemophilia cases

- PMLiVE

US researchers develop 3D technique to identify precancerous pancreatic lesions

PanIN lesions can lead to invasive ductal adenocarcinoma, which affects nearly half a million people globally

- PMLiVE

Alnylam presents positive late-stage results for RNAi therapeutic in ATTR with cardiomyopathy

Hereditary ATTR and wild-type ATTR are responsible for an estimated 350,000 cases globally

- PMLiVE

P-AI-n or g-AI-n?

Who will win in an AI-coloured world?

- PMLiVE

Roche’s subcutaneous Ocrevus granted EC approval to treat relapsing and primary MS

The injection has the same twice-yearly schedule as the previously approved intravenous infusion

Biogen Idec building

Biogen’s RoActemra biosimilar Tofidence approved by EC to treat arthritis and COVID-19

The regulator’s decision was supported by evidence demonstrating Tofidence’s similarity to the reference product

- PMLiVE

FDA approves argenx’s Vyvgart Hytrulo for rare neuromuscular disorder CIDP

Approximately 24,000 US patients are currently being treated for chronic inflammatory demyelinating polyneuropathy

- PMLiVE

New phase 2 study launched to evaluate triple drug combination in pancreatic cancer

The PRIMUS-006 study will evaluate Lilly/Genentech’s Gemzar in combination with Merck’s Keytruda and Immodulon’s IMM-101

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links